
The final agreement between the government and the American drug-maker on indemnity and procurement norms are still pending, though the two parties have arrived at an in-principle consensus, sources said.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2RZynwe
via
IFTTT
0 comments:
Post a Comment